Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination with Chemotherapy
Trial status:Recruiting
Study Identifier:
BNT327-02
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial details
Medical Condition
Study Drug
See more
Phase
Phase 2
Sex
Female & Male
Age
18+
Estimated Trial Date
Aug 2024 - Mar 2025
Protocol summary
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Trial locations
Location
Status
Location
Beverly Hills Cancer Center
Beverly Hills, California, United States, 90211
Status
Not yet recruiting
Location
Valkyrie Clinical Trials
Los Angeles, California, United States, 90067
Status
Recruiting
Location
Orchard Healthcare Research Inc.
Skokie, Illinois, United States, 60077
Status
Recruiting
Location
Helen G. Nassif Community Cancer Center
Cedar Rapids, Iowa, United States, 52403
Status
Not yet recruiting
Location
HealthPartners Frauenshuh Cancer Center
Saint Louis Park, Minnesota, United States, 55426
Status
Not yet recruiting
Location
Clinical Research Alliance Inc.
Westbury, New York, United States, 11590
Status
Recruiting